nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—bipolar disorder—Topiramate—obesity	0.133	1	CpDpCtD
Duloxetine—Serotonin Uptake Inhibitors—Sibutramine—obesity	0.131	0.372	CiPCiCtD
Duloxetine—Norepinephrine Uptake Inhibitors—Bupropion—obesity	0.116	0.332	CiPCiCtD
Duloxetine—NPY1R—obesity	0.107	0.696	CbGaD
Duloxetine—Norepinephrine Uptake Inhibitors—Sibutramine—obesity	0.104	0.296	CiPCiCtD
Duloxetine—Butenafine—Benzphetamine—obesity	0.0489	0.507	CrCrCtD
Duloxetine—Naftifine—Benzphetamine—obesity	0.0293	0.303	CrCrCtD
Duloxetine—HTR2C—obesity	0.0189	0.123	CbGaD
Duloxetine—Atomoxetine—Benzphetamine—obesity	0.0184	0.19	CrCrCtD
Duloxetine—SLC6A3—Diethylpropion—obesity	0.0162	0.0874	CbGbCtD
Duloxetine—SLC6A4—obesity	0.0157	0.102	CbGaD
Duloxetine—SLC6A3—Sibutramine—obesity	0.0123	0.0662	CbGbCtD
Duloxetine—SLC6A3—Phendimetrazine—obesity	0.0123	0.0662	CbGbCtD
Duloxetine—HTR2A—obesity	0.012	0.0785	CbGaD
Duloxetine—SLC6A2—Diethylpropion—obesity	0.0119	0.064	CbGbCtD
Duloxetine—SLC6A4—Sibutramine—obesity	0.0108	0.058	CbGbCtD
Duloxetine—SLC6A3—Benzphetamine—obesity	0.00933	0.0502	CbGbCtD
Duloxetine—SLC6A3—Phentermine—obesity	0.00933	0.0502	CbGbCtD
Duloxetine—SLC6A2—Phendimetrazine—obesity	0.00901	0.0485	CbGbCtD
Duloxetine—SLC6A2—Sibutramine—obesity	0.00901	0.0485	CbGbCtD
Duloxetine—SLC6A3—Phenylpropanolamine—obesity	0.0089	0.0479	CbGbCtD
Duloxetine—SLC6A4—Phentermine—obesity	0.00816	0.0439	CbGbCtD
Duloxetine—SLC6A3—Bupropion—obesity	0.00793	0.0427	CbGbCtD
Duloxetine—SLC6A3—Methamphetamine—obesity	0.00746	0.0401	CbGbCtD
Duloxetine—SLC6A2—Benzphetamine—obesity	0.00683	0.0367	CbGbCtD
Duloxetine—SLC6A2—Phentermine—obesity	0.00683	0.0367	CbGbCtD
Duloxetine—SLC6A4—Methamphetamine—obesity	0.00653	0.0351	CbGbCtD
Duloxetine—SLC6A2—Phenylpropanolamine—obesity	0.00651	0.035	CbGbCtD
Duloxetine—SLC6A2—Bupropion—obesity	0.00581	0.0312	CbGbCtD
Duloxetine—SLC6A2—Methamphetamine—obesity	0.00546	0.0294	CbGbCtD
Duloxetine—CYP1A2—Phentermine—obesity	0.00248	0.0134	CbGbCtD
Duloxetine—CYP1A2—Phenylpropanolamine—obesity	0.00237	0.0128	CbGbCtD
Duloxetine—CYP1A2—Bupropion—obesity	0.00211	0.0114	CbGbCtD
Duloxetine—CYP2D6—Phentermine—obesity	0.00205	0.011	CbGbCtD
Duloxetine—CYP2D6—Bupropion—obesity	0.00174	0.00937	CbGbCtD
Duloxetine—CYP2D6—Methamphetamine—obesity	0.00164	0.00881	CbGbCtD
Duloxetine—CYP1A2—Cimetidine—obesity	0.00155	0.00834	CbGbCtD
Duloxetine—CYP2D6—Cimetidine—obesity	0.00128	0.00687	CbGbCtD
Duloxetine—SLC6A2—sympathetic nervous system—obesity	0.000984	0.122	CbGeAlD
Duloxetine—SLC6A2—autonomic nervous system—obesity	0.000661	0.0821	CbGeAlD
Duloxetine—HTR2A—sympathetic nervous system—obesity	0.000591	0.0734	CbGeAlD
Duloxetine—HTR2A—vagus nerve—obesity	0.000573	0.0711	CbGeAlD
Duloxetine—NPY1R—adrenal cortex—obesity	0.000421	0.0522	CbGeAlD
Duloxetine—HTR2A—autonomic nervous system—obesity	0.000397	0.0493	CbGeAlD
Duloxetine—SLC6A3—hindbrain—obesity	0.000345	0.0428	CbGeAlD
Duloxetine—NPY1R—pituitary gland—obesity	0.00034	0.0422	CbGeAlD
Duloxetine—NPY1R—adipose tissue—obesity	0.000338	0.042	CbGeAlD
Duloxetine—SLC6A4—hindbrain—obesity	0.000316	0.0393	CbGeAlD
Duloxetine—NPY1R—adrenal gland—obesity	0.000304	0.0377	CbGeAlD
Duloxetine—NPY1R—endocrine gland—obesity	0.000263	0.0327	CbGeAlD
Duloxetine—NPY1R—liver—obesity	0.000237	0.0295	CbGeAlD
Duloxetine—SLC6A3—respiratory system—obesity	0.000211	0.0262	CbGeAlD
Duloxetine—Atomoxetine—NPY1R—obesity	0.0002	0.268	CrCbGaD
Duloxetine—SLC6A4—respiratory system—obesity	0.000193	0.024	CbGeAlD
Duloxetine—SLC6A2—respiratory system—obesity	0.00017	0.0211	CbGeAlD
Duloxetine—HTR2A—hindbrain—obesity	0.000167	0.0208	CbGeAlD
Duloxetine—CYP2D6—hindbrain—obesity	0.000153	0.0189	CbGeAlD
Duloxetine—CYP1A2—respiratory system—obesity	0.000131	0.0162	CbGeAlD
Duloxetine—SLC6A4—digestive system—obesity	0.000123	0.0152	CbGeAlD
Duloxetine—SLC6A2—adrenal gland—obesity	0.000103	0.0128	CbGeAlD
Duloxetine—HTR2A—respiratory system—obesity	0.000102	0.0127	CbGeAlD
Duloxetine—SLC6A4—endocrine gland—obesity	0.000102	0.0126	CbGeAlD
Duloxetine—SLC6A2—endocrine gland—obesity	8.94e-05	0.0111	CbGeAlD
Duloxetine—CYP1A2—digestive system—obesity	8.31e-05	0.0103	CbGeAlD
Duloxetine—Propranolol—ADRB3—obesity	8.06e-05	0.108	CrCbGaD
Duloxetine—HTR2A—cardiovascular system—obesity	7.83e-05	0.00972	CbGeAlD
Duloxetine—HTR2A—pituitary gland—obesity	6.93e-05	0.0086	CbGeAlD
Duloxetine—CYP1A2—endocrine gland—obesity	6.87e-05	0.00853	CbGeAlD
Duloxetine—Protriptyline—SLC6A4—obesity	6.68e-05	0.0896	CrCbGaD
Duloxetine—HTR2A—digestive system—obesity	6.5e-05	0.00807	CbGeAlD
Duloxetine—HTR2A—adrenal gland—obesity	6.19e-05	0.00769	CbGeAlD
Duloxetine—CYP1A2—liver—obesity	6.19e-05	0.00769	CbGeAlD
Duloxetine—CYP2D6—digestive system—obesity	5.92e-05	0.00735	CbGeAlD
Duloxetine—Fluoxetine—HTR2C—obesity	5.51e-05	0.0738	CrCbGaD
Duloxetine—HTR2A—endocrine gland—obesity	5.37e-05	0.00667	CbGeAlD
Duloxetine—CYP2D6—endocrine gland—obesity	4.89e-05	0.00607	CbGeAlD
Duloxetine—HTR2A—liver—obesity	4.84e-05	0.00601	CbGeAlD
Duloxetine—Fluoxetine—SLC6A4—obesity	4.56e-05	0.0612	CrCbGaD
Duloxetine—CYP2D6—liver—obesity	4.41e-05	0.00547	CbGeAlD
Duloxetine—Atomoxetine—HTR1B—obesity	4.34e-05	0.0582	CrCbGaD
Duloxetine—Propranolol—HTR1B—obesity	4.12e-05	0.0553	CrCbGaD
Duloxetine—Propranolol—ADRB1—obesity	3.65e-05	0.0489	CrCbGaD
Duloxetine—Atomoxetine—HTR2C—obesity	3.54e-05	0.0474	CrCbGaD
Duloxetine—Fluoxetine—HTR2A—obesity	3.51e-05	0.047	CrCbGaD
Duloxetine—Propranolol—ADRB2—obesity	3.07e-05	0.0411	CrCbGaD
Duloxetine—Atomoxetine—SLC6A4—obesity	2.93e-05	0.0393	CrCbGaD
Duloxetine—Fluoxetine—ALB—obesity	2.4e-05	0.0322	CrCbGaD
Duloxetine—Dry mouth—Orlistat—obesity	2.25e-05	0.000505	CcSEcCtD
Duloxetine—Atomoxetine—HTR2A—obesity	2.25e-05	0.0302	CrCbGaD
Duloxetine—Flatulence—Bupropion—obesity	2.25e-05	0.000504	CcSEcCtD
Duloxetine—Dehydration—Topiramate—obesity	2.25e-05	0.000503	CcSEcCtD
Duloxetine—Tension—Bupropion—obesity	2.24e-05	0.000502	CcSEcCtD
Duloxetine—Dysgeusia—Bupropion—obesity	2.24e-05	0.000501	CcSEcCtD
Duloxetine—Liver function test abnormal—Topiramate—obesity	2.23e-05	0.0005	CcSEcCtD
Duloxetine—Myalgia—Sibutramine—obesity	2.23e-05	0.0005	CcSEcCtD
Duloxetine—Chest pain—Sibutramine—obesity	2.23e-05	0.0005	CcSEcCtD
Duloxetine—Arthralgia—Sibutramine—obesity	2.23e-05	0.0005	CcSEcCtD
Duloxetine—Anxiety—Sibutramine—obesity	2.22e-05	0.000498	CcSEcCtD
Duloxetine—Nervousness—Bupropion—obesity	2.22e-05	0.000497	CcSEcCtD
Duloxetine—Anaphylactic shock—Orlistat—obesity	2.21e-05	0.000495	CcSEcCtD
Duloxetine—Oedema—Orlistat—obesity	2.21e-05	0.000495	CcSEcCtD
Duloxetine—Back pain—Bupropion—obesity	2.21e-05	0.000495	CcSEcCtD
Duloxetine—Orthostatic hypotension—Topiramate—obesity	2.21e-05	0.000494	CcSEcCtD
Duloxetine—Abdominal pain upper—Topiramate—obesity	2.21e-05	0.000494	CcSEcCtD
Duloxetine—Discomfort—Sibutramine—obesity	2.2e-05	0.000494	CcSEcCtD
Duloxetine—Muscle spasms—Bupropion—obesity	2.2e-05	0.000492	CcSEcCtD
Duloxetine—Infection—Orlistat—obesity	2.2e-05	0.000492	CcSEcCtD
Duloxetine—Breast disorder—Topiramate—obesity	2.18e-05	0.000489	CcSEcCtD
Duloxetine—Dry mouth—Sibutramine—obesity	2.18e-05	0.000489	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Topiramate—obesity	2.18e-05	0.000487	CcSEcCtD
Duloxetine—Nervous system disorder—Orlistat—obesity	2.17e-05	0.000485	CcSEcCtD
Duloxetine—Nasopharyngitis—Topiramate—obesity	2.16e-05	0.000484	CcSEcCtD
Duloxetine—Confusional state—Sibutramine—obesity	2.16e-05	0.000483	CcSEcCtD
Duloxetine—Vision blurred—Bupropion—obesity	2.15e-05	0.000482	CcSEcCtD
Duloxetine—Skin disorder—Orlistat—obesity	2.15e-05	0.000481	CcSEcCtD
Duloxetine—Tremor—Bupropion—obesity	2.14e-05	0.000479	CcSEcCtD
Duloxetine—Gastritis—Topiramate—obesity	2.14e-05	0.000479	CcSEcCtD
Duloxetine—Oedema—Sibutramine—obesity	2.14e-05	0.000479	CcSEcCtD
Duloxetine—Anaphylactic shock—Sibutramine—obesity	2.14e-05	0.000479	CcSEcCtD
Duloxetine—Hyperhidrosis—Orlistat—obesity	2.14e-05	0.000478	CcSEcCtD
Duloxetine—Muscular weakness—Topiramate—obesity	2.13e-05	0.000477	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Topiramate—obesity	2.13e-05	0.000477	CcSEcCtD
Duloxetine—Infection—Sibutramine—obesity	2.12e-05	0.000476	CcSEcCtD
Duloxetine—Ill-defined disorder—Bupropion—obesity	2.12e-05	0.000475	CcSEcCtD
Duloxetine—Anaemia—Bupropion—obesity	2.11e-05	0.000473	CcSEcCtD
Duloxetine—Shock—Sibutramine—obesity	2.1e-05	0.000471	CcSEcCtD
Duloxetine—Agitation—Bupropion—obesity	2.1e-05	0.00047	CcSEcCtD
Duloxetine—Thrombocytopenia—Sibutramine—obesity	2.09e-05	0.000469	CcSEcCtD
Duloxetine—Dysphagia—Topiramate—obesity	2.09e-05	0.000468	CcSEcCtD
Duloxetine—Angioedema—Bupropion—obesity	2.09e-05	0.000467	CcSEcCtD
Duloxetine—Tachycardia—Sibutramine—obesity	2.09e-05	0.000467	CcSEcCtD
Duloxetine—Skin disorder—Sibutramine—obesity	2.08e-05	0.000465	CcSEcCtD
Duloxetine—Hyperhidrosis—Sibutramine—obesity	2.07e-05	0.000463	CcSEcCtD
Duloxetine—Malaise—Bupropion—obesity	2.06e-05	0.000461	CcSEcCtD
Duloxetine—Vertigo—Bupropion—obesity	2.05e-05	0.00046	CcSEcCtD
Duloxetine—Syncope—Bupropion—obesity	2.05e-05	0.000459	CcSEcCtD
Duloxetine—Pancreatitis—Topiramate—obesity	2.05e-05	0.000459	CcSEcCtD
Duloxetine—Leukopenia—Bupropion—obesity	2.04e-05	0.000458	CcSEcCtD
Duloxetine—Anorexia—Sibutramine—obesity	2.04e-05	0.000457	CcSEcCtD
Duloxetine—Sweating increased—Topiramate—obesity	2.03e-05	0.000456	CcSEcCtD
Duloxetine—Palpitations—Bupropion—obesity	2.02e-05	0.000452	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Orlistat—obesity	2.01e-05	0.000451	CcSEcCtD
Duloxetine—Loss of consciousness—Bupropion—obesity	2.01e-05	0.00045	CcSEcCtD
Duloxetine—Abdominal discomfort—Topiramate—obesity	2e-05	0.000448	CcSEcCtD
Duloxetine—Insomnia—Orlistat—obesity	2e-05	0.000448	CcSEcCtD
Duloxetine—Cough—Bupropion—obesity	1.99e-05	0.000446	CcSEcCtD
Duloxetine—Paraesthesia—Orlistat—obesity	1.98e-05	0.000444	CcSEcCtD
Duloxetine—Convulsion—Bupropion—obesity	1.98e-05	0.000443	CcSEcCtD
Duloxetine—Hypertension—Bupropion—obesity	1.97e-05	0.000442	CcSEcCtD
Duloxetine—Dysuria—Topiramate—obesity	1.95e-05	0.000437	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Sibutramine—obesity	1.95e-05	0.000436	CcSEcCtD
Duloxetine—Dyspepsia—Orlistat—obesity	1.95e-05	0.000436	CcSEcCtD
Duloxetine—Chest pain—Bupropion—obesity	1.94e-05	0.000436	CcSEcCtD
Duloxetine—Arthralgia—Bupropion—obesity	1.94e-05	0.000436	CcSEcCtD
Duloxetine—Myalgia—Bupropion—obesity	1.94e-05	0.000436	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Topiramate—obesity	1.94e-05	0.000435	CcSEcCtD
Duloxetine—Anxiety—Bupropion—obesity	1.94e-05	0.000434	CcSEcCtD
Duloxetine—Insomnia—Sibutramine—obesity	1.93e-05	0.000433	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	1.93e-05	0.000433	CcSEcCtD
Duloxetine—Pollakiuria—Topiramate—obesity	1.93e-05	0.000432	CcSEcCtD
Duloxetine—Erectile dysfunction—Topiramate—obesity	1.92e-05	0.000431	CcSEcCtD
Duloxetine—Discomfort—Bupropion—obesity	1.92e-05	0.00043	CcSEcCtD
Duloxetine—Decreased appetite—Orlistat—obesity	1.92e-05	0.00043	CcSEcCtD
Duloxetine—Paraesthesia—Sibutramine—obesity	1.92e-05	0.00043	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Orlistat—obesity	1.91e-05	0.000427	CcSEcCtD
Duloxetine—Photosensitivity reaction—Topiramate—obesity	1.91e-05	0.000427	CcSEcCtD
Duloxetine—Fatigue—Orlistat—obesity	1.91e-05	0.000427	CcSEcCtD
Duloxetine—Dry mouth—Bupropion—obesity	1.9e-05	0.000426	CcSEcCtD
Duloxetine—Somnolence—Sibutramine—obesity	1.9e-05	0.000426	CcSEcCtD
Duloxetine—Weight increased—Topiramate—obesity	1.9e-05	0.000426	CcSEcCtD
Duloxetine—Weight decreased—Topiramate—obesity	1.89e-05	0.000423	CcSEcCtD
Duloxetine—Pain—Orlistat—obesity	1.89e-05	0.000423	CcSEcCtD
Duloxetine—Hyperglycaemia—Topiramate—obesity	1.88e-05	0.000422	CcSEcCtD
Duloxetine—Dyspepsia—Sibutramine—obesity	1.88e-05	0.000422	CcSEcCtD
Duloxetine—Confusional state—Bupropion—obesity	1.88e-05	0.000421	CcSEcCtD
Duloxetine—Anaphylactic shock—Bupropion—obesity	1.86e-05	0.000418	CcSEcCtD
Duloxetine—Oedema—Bupropion—obesity	1.86e-05	0.000418	CcSEcCtD
Duloxetine—Infestation NOS—Topiramate—obesity	1.86e-05	0.000417	CcSEcCtD
Duloxetine—Infestation—Topiramate—obesity	1.86e-05	0.000417	CcSEcCtD
Duloxetine—Decreased appetite—Sibutramine—obesity	1.86e-05	0.000416	CcSEcCtD
Duloxetine—Infection—Bupropion—obesity	1.85e-05	0.000415	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Topiramate—obesity	1.85e-05	0.000414	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Sibutramine—obesity	1.85e-05	0.000413	CcSEcCtD
Duloxetine—Shock—Bupropion—obesity	1.83e-05	0.000411	CcSEcCtD
Duloxetine—Renal failure—Topiramate—obesity	1.83e-05	0.00041	CcSEcCtD
Duloxetine—Constipation—Sibutramine—obesity	1.83e-05	0.00041	CcSEcCtD
Duloxetine—Pain—Sibutramine—obesity	1.83e-05	0.00041	CcSEcCtD
Duloxetine—Nervous system disorder—Bupropion—obesity	1.83e-05	0.000409	CcSEcCtD
Duloxetine—Thrombocytopenia—Bupropion—obesity	1.83e-05	0.000409	CcSEcCtD
Duloxetine—Feeling abnormal—Orlistat—obesity	1.82e-05	0.000408	CcSEcCtD
Duloxetine—Tachycardia—Bupropion—obesity	1.82e-05	0.000408	CcSEcCtD
Duloxetine—Stomatitis—Topiramate—obesity	1.82e-05	0.000407	CcSEcCtD
Duloxetine—Skin disorder—Bupropion—obesity	1.81e-05	0.000406	CcSEcCtD
Duloxetine—Conjunctivitis—Topiramate—obesity	1.81e-05	0.000405	CcSEcCtD
Duloxetine—Urinary tract infection—Topiramate—obesity	1.81e-05	0.000405	CcSEcCtD
Duloxetine—Gastrointestinal pain—Orlistat—obesity	1.81e-05	0.000405	CcSEcCtD
Duloxetine—Hyperhidrosis—Bupropion—obesity	1.8e-05	0.000404	CcSEcCtD
Duloxetine—Anorexia—Bupropion—obesity	1.78e-05	0.000398	CcSEcCtD
Duloxetine—Feeling abnormal—Sibutramine—obesity	1.76e-05	0.000395	CcSEcCtD
Duloxetine—Epistaxis—Topiramate—obesity	1.76e-05	0.000393	CcSEcCtD
Duloxetine—Urticaria—Orlistat—obesity	1.76e-05	0.000393	CcSEcCtD
Duloxetine—Gastrointestinal pain—Sibutramine—obesity	1.75e-05	0.000392	CcSEcCtD
Duloxetine—Abdominal pain—Orlistat—obesity	1.75e-05	0.000391	CcSEcCtD
Duloxetine—Body temperature increased—Orlistat—obesity	1.75e-05	0.000391	CcSEcCtD
Duloxetine—Urticaria—Sibutramine—obesity	1.7e-05	0.00038	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Bupropion—obesity	1.7e-05	0.00038	CcSEcCtD
Duloxetine—Abdominal pain—Sibutramine—obesity	1.69e-05	0.000379	CcSEcCtD
Duloxetine—Body temperature increased—Sibutramine—obesity	1.69e-05	0.000379	CcSEcCtD
Duloxetine—Insomnia—Bupropion—obesity	1.69e-05	0.000378	CcSEcCtD
Duloxetine—Haemoglobin—Topiramate—obesity	1.68e-05	0.000376	CcSEcCtD
Duloxetine—Paraesthesia—Bupropion—obesity	1.67e-05	0.000375	CcSEcCtD
Duloxetine—Hepatitis—Topiramate—obesity	1.67e-05	0.000374	CcSEcCtD
Duloxetine—Haemorrhage—Topiramate—obesity	1.67e-05	0.000374	CcSEcCtD
Duloxetine—Hypoaesthesia—Topiramate—obesity	1.66e-05	0.000373	CcSEcCtD
Duloxetine—Hallucination—Topiramate—obesity	1.66e-05	0.000373	CcSEcCtD
Duloxetine—Pharyngitis—Topiramate—obesity	1.66e-05	0.000372	CcSEcCtD
Duloxetine—Somnolence—Bupropion—obesity	1.66e-05	0.000371	CcSEcCtD
Duloxetine—Urinary tract disorder—Topiramate—obesity	1.65e-05	0.00037	CcSEcCtD
Duloxetine—Oedema peripheral—Topiramate—obesity	1.65e-05	0.000369	CcSEcCtD
Duloxetine—Connective tissue disorder—Topiramate—obesity	1.64e-05	0.000368	CcSEcCtD
Duloxetine—Dyspepsia—Bupropion—obesity	1.64e-05	0.000368	CcSEcCtD
Duloxetine—Urethral disorder—Topiramate—obesity	1.64e-05	0.000367	CcSEcCtD
Duloxetine—Hypersensitivity—Orlistat—obesity	1.63e-05	0.000365	CcSEcCtD
Duloxetine—Decreased appetite—Bupropion—obesity	1.62e-05	0.000363	CcSEcCtD
Duloxetine—Visual impairment—Topiramate—obesity	1.61e-05	0.000361	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Bupropion—obesity	1.61e-05	0.00036	CcSEcCtD
Duloxetine—Fatigue—Bupropion—obesity	1.61e-05	0.00036	CcSEcCtD
Duloxetine—Constipation—Bupropion—obesity	1.59e-05	0.000357	CcSEcCtD
Duloxetine—Pain—Bupropion—obesity	1.59e-05	0.000357	CcSEcCtD
Duloxetine—Asthenia—Orlistat—obesity	1.59e-05	0.000355	CcSEcCtD
Duloxetine—Erythema multiforme—Topiramate—obesity	1.58e-05	0.000354	CcSEcCtD
Duloxetine—Hypersensitivity—Sibutramine—obesity	1.58e-05	0.000353	CcSEcCtD
Duloxetine—Pruritus—Orlistat—obesity	1.56e-05	0.00035	CcSEcCtD
Duloxetine—Eye disorder—Topiramate—obesity	1.56e-05	0.00035	CcSEcCtD
Duloxetine—Tinnitus—Topiramate—obesity	1.56e-05	0.000349	CcSEcCtD
Duloxetine—Cardiac disorder—Topiramate—obesity	1.55e-05	0.000347	CcSEcCtD
Duloxetine—Flushing—Topiramate—obesity	1.55e-05	0.000347	CcSEcCtD
Duloxetine—Feeling abnormal—Bupropion—obesity	1.54e-05	0.000344	CcSEcCtD
Duloxetine—Asthenia—Sibutramine—obesity	1.53e-05	0.000344	CcSEcCtD
Duloxetine—Gastrointestinal pain—Bupropion—obesity	1.52e-05	0.000341	CcSEcCtD
Duloxetine—Angiopathy—Topiramate—obesity	1.52e-05	0.00034	CcSEcCtD
Duloxetine—Pruritus—Sibutramine—obesity	1.51e-05	0.000339	CcSEcCtD
Duloxetine—Diarrhoea—Orlistat—obesity	1.51e-05	0.000339	CcSEcCtD
Duloxetine—Immune system disorder—Topiramate—obesity	1.51e-05	0.000338	CcSEcCtD
Duloxetine—Mediastinal disorder—Topiramate—obesity	1.51e-05	0.000337	CcSEcCtD
Duloxetine—Chills—Topiramate—obesity	1.5e-05	0.000336	CcSEcCtD
Duloxetine—Urticaria—Bupropion—obesity	1.48e-05	0.000332	CcSEcCtD
Duloxetine—Alopecia—Topiramate—obesity	1.48e-05	0.000331	CcSEcCtD
Duloxetine—Body temperature increased—Bupropion—obesity	1.47e-05	0.00033	CcSEcCtD
Duloxetine—Abdominal pain—Bupropion—obesity	1.47e-05	0.00033	CcSEcCtD
Duloxetine—Mental disorder—Topiramate—obesity	1.46e-05	0.000328	CcSEcCtD
Duloxetine—Diarrhoea—Sibutramine—obesity	1.46e-05	0.000328	CcSEcCtD
Duloxetine—Dizziness—Orlistat—obesity	1.46e-05	0.000327	CcSEcCtD
Duloxetine—Malnutrition—Topiramate—obesity	1.46e-05	0.000326	CcSEcCtD
Duloxetine—Erythema—Topiramate—obesity	1.46e-05	0.000326	CcSEcCtD
Duloxetine—Flatulence—Topiramate—obesity	1.43e-05	0.000321	CcSEcCtD
Duloxetine—Tension—Topiramate—obesity	1.43e-05	0.00032	CcSEcCtD
Duloxetine—Dysgeusia—Topiramate—obesity	1.43e-05	0.000319	CcSEcCtD
Duloxetine—Dizziness—Sibutramine—obesity	1.41e-05	0.000317	CcSEcCtD
Duloxetine—Nervousness—Topiramate—obesity	1.41e-05	0.000317	CcSEcCtD
Duloxetine—Back pain—Topiramate—obesity	1.41e-05	0.000315	CcSEcCtD
Duloxetine—Vomiting—Orlistat—obesity	1.41e-05	0.000315	CcSEcCtD
Duloxetine—Muscle spasms—Topiramate—obesity	1.4e-05	0.000313	CcSEcCtD
Duloxetine—Rash—Orlistat—obesity	1.39e-05	0.000312	CcSEcCtD
Duloxetine—Dermatitis—Orlistat—obesity	1.39e-05	0.000312	CcSEcCtD
Duloxetine—Headache—Orlistat—obesity	1.38e-05	0.00031	CcSEcCtD
Duloxetine—Hypersensitivity—Bupropion—obesity	1.37e-05	0.000308	CcSEcCtD
Duloxetine—Vision blurred—Topiramate—obesity	1.37e-05	0.000307	CcSEcCtD
Duloxetine—Tremor—Topiramate—obesity	1.36e-05	0.000305	CcSEcCtD
Duloxetine—Vomiting—Sibutramine—obesity	1.36e-05	0.000305	CcSEcCtD
Duloxetine—Ill-defined disorder—Topiramate—obesity	1.35e-05	0.000302	CcSEcCtD
Duloxetine—Rash—Sibutramine—obesity	1.35e-05	0.000302	CcSEcCtD
Duloxetine—Dermatitis—Sibutramine—obesity	1.35e-05	0.000302	CcSEcCtD
Duloxetine—Anaemia—Topiramate—obesity	1.35e-05	0.000301	CcSEcCtD
Duloxetine—Headache—Sibutramine—obesity	1.34e-05	0.0003	CcSEcCtD
Duloxetine—Asthenia—Bupropion—obesity	1.34e-05	0.0003	CcSEcCtD
Duloxetine—Agitation—Topiramate—obesity	1.34e-05	0.0003	CcSEcCtD
Duloxetine—Pruritus—Bupropion—obesity	1.32e-05	0.000295	CcSEcCtD
Duloxetine—Nausea—Orlistat—obesity	1.31e-05	0.000294	CcSEcCtD
Duloxetine—Malaise—Topiramate—obesity	1.31e-05	0.000294	CcSEcCtD
Duloxetine—Vertigo—Topiramate—obesity	1.31e-05	0.000293	CcSEcCtD
Duloxetine—Syncope—Topiramate—obesity	1.31e-05	0.000292	CcSEcCtD
Duloxetine—Leukopenia—Topiramate—obesity	1.3e-05	0.000292	CcSEcCtD
Duloxetine—Palpitations—Topiramate—obesity	1.29e-05	0.000288	CcSEcCtD
Duloxetine—Loss of consciousness—Topiramate—obesity	1.28e-05	0.000286	CcSEcCtD
Duloxetine—Diarrhoea—Bupropion—obesity	1.28e-05	0.000286	CcSEcCtD
Duloxetine—Nausea—Sibutramine—obesity	1.27e-05	0.000284	CcSEcCtD
Duloxetine—Cough—Topiramate—obesity	1.27e-05	0.000284	CcSEcCtD
Duloxetine—Convulsion—Topiramate—obesity	1.26e-05	0.000282	CcSEcCtD
Duloxetine—Hypertension—Topiramate—obesity	1.26e-05	0.000281	CcSEcCtD
Duloxetine—Arthralgia—Topiramate—obesity	1.24e-05	0.000277	CcSEcCtD
Duloxetine—Myalgia—Topiramate—obesity	1.24e-05	0.000277	CcSEcCtD
Duloxetine—Chest pain—Topiramate—obesity	1.24e-05	0.000277	CcSEcCtD
Duloxetine—Anxiety—Topiramate—obesity	1.23e-05	0.000277	CcSEcCtD
Duloxetine—Dizziness—Bupropion—obesity	1.23e-05	0.000276	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	1.23e-05	0.000276	CcSEcCtD
Duloxetine—Discomfort—Topiramate—obesity	1.22e-05	0.000274	CcSEcCtD
Duloxetine—Dry mouth—Topiramate—obesity	1.21e-05	0.000271	CcSEcCtD
Duloxetine—Confusional state—Topiramate—obesity	1.2e-05	0.000268	CcSEcCtD
Duloxetine—Oedema—Topiramate—obesity	1.19e-05	0.000266	CcSEcCtD
Duloxetine—Vomiting—Bupropion—obesity	1.19e-05	0.000265	CcSEcCtD
Duloxetine—Infection—Topiramate—obesity	1.18e-05	0.000264	CcSEcCtD
Duloxetine—Rash—Bupropion—obesity	1.18e-05	0.000263	CcSEcCtD
Duloxetine—Dermatitis—Bupropion—obesity	1.17e-05	0.000263	CcSEcCtD
Duloxetine—Shock—Topiramate—obesity	1.17e-05	0.000262	CcSEcCtD
Duloxetine—Headache—Bupropion—obesity	1.17e-05	0.000262	CcSEcCtD
Duloxetine—Nervous system disorder—Topiramate—obesity	1.16e-05	0.000261	CcSEcCtD
Duloxetine—Thrombocytopenia—Topiramate—obesity	1.16e-05	0.00026	CcSEcCtD
Duloxetine—Tachycardia—Topiramate—obesity	1.16e-05	0.00026	CcSEcCtD
Duloxetine—Skin disorder—Topiramate—obesity	1.15e-05	0.000258	CcSEcCtD
Duloxetine—Hyperhidrosis—Topiramate—obesity	1.15e-05	0.000257	CcSEcCtD
Duloxetine—Anorexia—Topiramate—obesity	1.13e-05	0.000254	CcSEcCtD
Duloxetine—Nausea—Bupropion—obesity	1.11e-05	0.000248	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Topiramate—obesity	1.08e-05	0.000242	CcSEcCtD
Duloxetine—Insomnia—Topiramate—obesity	1.07e-05	0.000241	CcSEcCtD
Duloxetine—Paraesthesia—Topiramate—obesity	1.07e-05	0.000239	CcSEcCtD
Duloxetine—Somnolence—Topiramate—obesity	1.06e-05	0.000236	CcSEcCtD
Duloxetine—Dyspepsia—Topiramate—obesity	1.05e-05	0.000234	CcSEcCtD
Duloxetine—Decreased appetite—Topiramate—obesity	1.03e-05	0.000231	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Topiramate—obesity	1.03e-05	0.00023	CcSEcCtD
Duloxetine—Fatigue—Topiramate—obesity	1.02e-05	0.000229	CcSEcCtD
Duloxetine—Constipation—Topiramate—obesity	1.02e-05	0.000227	CcSEcCtD
Duloxetine—Pain—Topiramate—obesity	1.02e-05	0.000227	CcSEcCtD
Duloxetine—Feeling abnormal—Topiramate—obesity	9.79e-06	0.000219	CcSEcCtD
Duloxetine—Gastrointestinal pain—Topiramate—obesity	9.71e-06	0.000218	CcSEcCtD
Duloxetine—Urticaria—Topiramate—obesity	9.44e-06	0.000211	CcSEcCtD
Duloxetine—Abdominal pain—Topiramate—obesity	9.39e-06	0.00021	CcSEcCtD
Duloxetine—Body temperature increased—Topiramate—obesity	9.39e-06	0.00021	CcSEcCtD
Duloxetine—Hypersensitivity—Topiramate—obesity	8.75e-06	0.000196	CcSEcCtD
Duloxetine—Asthenia—Topiramate—obesity	8.52e-06	0.000191	CcSEcCtD
Duloxetine—Pruritus—Topiramate—obesity	8.4e-06	0.000188	CcSEcCtD
Duloxetine—Diarrhoea—Topiramate—obesity	8.13e-06	0.000182	CcSEcCtD
Duloxetine—Dizziness—Topiramate—obesity	7.86e-06	0.000176	CcSEcCtD
Duloxetine—Vomiting—Topiramate—obesity	7.55e-06	0.000169	CcSEcCtD
Duloxetine—Rash—Topiramate—obesity	7.49e-06	0.000168	CcSEcCtD
Duloxetine—Dermatitis—Topiramate—obesity	7.48e-06	0.000168	CcSEcCtD
Duloxetine—Headache—Topiramate—obesity	7.44e-06	0.000167	CcSEcCtD
Duloxetine—Nausea—Topiramate—obesity	7.06e-06	0.000158	CcSEcCtD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3R1—obesity	1.02e-06	3.79e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IRS1—obesity	1.02e-06	3.79e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NAMPT—obesity	1.02e-06	3.79e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LIPC—obesity	1.01e-06	3.76e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GCK—obesity	1.01e-06	3.76e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FOXO3—obesity	1.01e-06	3.74e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOC3—obesity	1.01e-06	3.74e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—obesity	1.01e-06	3.74e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRB2—obesity	1.01e-06	3.73e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LPL—obesity	1.01e-06	3.73e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FOXO1—obesity	9.99e-07	3.7e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RPS6KB1—obesity	9.97e-07	3.7e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SOCS1—obesity	9.92e-07	3.68e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CLOCK—obesity	9.9e-07	3.67e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC22A1—obesity	9.9e-07	3.67e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—obesity	9.88e-07	3.66e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CB—obesity	9.87e-07	3.66e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—POMC—obesity	9.84e-07	3.65e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CD—obesity	9.83e-07	3.65e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SOCS3—obesity	9.8e-07	3.63e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CETP—obesity	9.79e-07	3.63e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—obesity	9.78e-07	3.63e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—INS—obesity	9.78e-07	3.63e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—obesity	9.76e-07	3.62e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SDC1—obesity	9.68e-07	3.59e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SULT2A1—obesity	9.65e-07	3.58e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GLP1R—obesity	9.65e-07	3.58e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL2—obesity	9.62e-07	3.57e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GNB3—obesity	9.6e-07	3.56e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKR1C3—obesity	9.53e-07	3.53e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—DPYD—obesity	9.49e-07	3.52e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1—obesity	9.46e-07	3.51e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TYK2—obesity	9.46e-07	3.51e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT2—obesity	9.45e-07	3.5e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CB—obesity	9.44e-07	3.5e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF2—obesity	9.42e-07	3.49e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—RHOA—obesity	9.38e-07	3.48e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SCARB1—obesity	9.38e-07	3.48e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GNAS—obesity	9.34e-07	3.46e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3R1—obesity	9.29e-07	3.44e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRKCD—obesity	9.27e-07	3.44e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOB—obesity	9.15e-07	3.39e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PRKAR2B—obesity	9.14e-07	3.39e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SREBF1—obesity	9.1e-07	3.37e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CD—obesity	9.08e-07	3.37e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HTR2A—obesity	9.07e-07	3.36e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—DCN—obesity	9.07e-07	3.36e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—C3—obesity	9.06e-07	3.36e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CA—obesity	9e-07	3.34e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SERPINE1—obesity	8.99e-07	3.33e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL5—obesity	8.93e-07	3.31e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—obesity	8.91e-07	3.3e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GOT2—obesity	8.86e-07	3.28e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CPT1A—obesity	8.82e-07	3.27e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TYK2—obesity	8.74e-07	3.24e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LPL—obesity	8.74e-07	3.24e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FOXO1—obesity	8.67e-07	3.21e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RHOA—obesity	8.67e-07	3.21e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—FASN—obesity	8.67e-07	3.21e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RPS6KB1—obesity	8.66e-07	3.21e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NAMPT—obesity	8.65e-07	3.21e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—BCHE—obesity	8.63e-07	3.2e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IRS2—obesity	8.62e-07	3.19e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGT—obesity	8.61e-07	3.19e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—obesity	8.6e-07	3.19e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LIPC—obesity	8.6e-07	3.19e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GCK—obesity	8.6e-07	3.19e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3R1—obesity	8.58e-07	3.18e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOS3—obesity	8.58e-07	3.18e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CB—obesity	8.57e-07	3.18e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOC3—obesity	8.54e-07	3.17e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—obesity	8.48e-07	3.14e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LEP—obesity	8.43e-07	3.13e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOE—obesity	8.43e-07	3.13e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CAV1—obesity	8.35e-07	3.1e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOA1—obesity	8.34e-07	3.09e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP2E1—obesity	8.33e-07	3.09e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CETP—obesity	8.3e-07	3.07e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NQO1—obesity	8.23e-07	3.05e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SDC1—obesity	8.2e-07	3.04e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—obesity	8.17e-07	3.03e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKR1C3—obesity	8.07e-07	2.99e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ESR1—obesity	8.05e-07	2.98e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRKCD—obesity	8.05e-07	2.98e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—F2—obesity	7.95e-07	2.95e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRKCB—obesity	7.95e-07	2.95e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SCARB1—obesity	7.94e-07	2.94e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MTOR—obesity	7.92e-07	2.94e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CB—obesity	7.92e-07	2.94e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GCG—obesity	7.89e-07	2.93e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC2A4—obesity	7.89e-07	2.93e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—C3—obesity	7.87e-07	2.92e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BAD—obesity	7.86e-07	2.91e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—obesity	7.83e-07	2.9e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYCS—obesity	7.79e-07	2.89e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—obesity	7.73e-07	2.87e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SREBF1—obesity	7.71e-07	2.86e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GGT1—obesity	7.64e-07	2.83e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GOT1—obesity	7.64e-07	2.83e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CG—obesity	7.61e-07	2.82e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NCOA1—obesity	7.53e-07	2.79e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IRS1—obesity	7.52e-07	2.79e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GOT2—obesity	7.5e-07	2.78e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IRS2—obesity	7.48e-07	2.77e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGT—obesity	7.47e-07	2.77e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—STK11—obesity	7.42e-07	2.75e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP19A1—obesity	7.42e-07	2.75e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—obesity	7.4e-07	2.74e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—obesity	7.35e-07	2.72e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—FASN—obesity	7.34e-07	2.72e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOE—obesity	7.32e-07	2.71e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LEP—obesity	7.32e-07	2.71e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—BCHE—obesity	7.31e-07	2.71e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CAV1—obesity	7.26e-07	2.69e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—POMC—obesity	7.24e-07	2.69e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOA1—obesity	7.24e-07	2.68e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—obesity	7.24e-07	2.68e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—INS—obesity	7.2e-07	2.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL2—obesity	7.09e-07	2.63e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2E1—obesity	7.05e-07	2.61e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ESR1—obesity	6.99e-07	2.59e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NQO1—obesity	6.97e-07	2.59e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1—obesity	6.97e-07	2.58e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT2—obesity	6.96e-07	2.58e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—F2—obesity	6.91e-07	2.56e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRKCB—obesity	6.91e-07	2.56e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—COMT—obesity	6.9e-07	2.56e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—obesity	6.88e-07	2.55e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—obesity	6.83e-07	2.53e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BAD—obesity	6.82e-07	2.53e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GNB3—obesity	6.8e-07	2.52e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARGC1A—obesity	6.8e-07	2.52e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMOX1—obesity	6.77e-07	2.51e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—obesity	6.77e-07	2.51e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK8—obesity	6.69e-07	2.48e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CD—obesity	6.69e-07	2.48e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC2A4—obesity	6.69e-07	2.48e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GCG—obesity	6.69e-07	2.48e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—obesity	6.68e-07	2.47e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—obesity	6.63e-07	2.46e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GNAS—obesity	6.62e-07	2.46e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SERPINE1—obesity	6.62e-07	2.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CG—obesity	6.61e-07	2.45e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYCS—obesity	6.6e-07	2.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IRS1—obesity	6.53e-07	2.42e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOB—obesity	6.49e-07	2.4e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GGT1—obesity	6.48e-07	2.4e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GOT1—obesity	6.48e-07	2.4e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TYK2—obesity	6.44e-07	2.39e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RHOA—obesity	6.38e-07	2.37e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NCOA1—obesity	6.38e-07	2.36e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3R1—obesity	6.32e-07	2.34e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOS3—obesity	6.32e-07	2.34e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—POMC—obesity	6.29e-07	2.33e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—STK11—obesity	6.29e-07	2.33e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP19A1—obesity	6.29e-07	2.33e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—INS—obesity	6.26e-07	2.32e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LPL—obesity	6.19e-07	2.3e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL2—obesity	6.15e-07	2.28e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—obesity	6.12e-07	2.27e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1—obesity	6.05e-07	2.24e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT2—obesity	6.05e-07	2.24e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GPX1—obesity	6.04e-07	2.24e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—obesity	6.02e-07	2.23e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CD36—obesity	5.88e-07	2.18e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—COMT—obesity	5.84e-07	2.17e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CB—obesity	5.83e-07	2.16e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MTOR—obesity	5.83e-07	2.16e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CD—obesity	5.81e-07	2.15e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARGC1A—obesity	5.76e-07	2.14e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GNB3—obesity	5.76e-07	2.14e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—obesity	5.75e-07	2.13e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SERPINE1—obesity	5.75e-07	2.13e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMOX1—obesity	5.74e-07	2.13e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—obesity	5.69e-07	2.11e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—obesity	5.67e-07	2.1e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GNAS—obesity	5.61e-07	2.08e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TYK2—obesity	5.59e-07	2.07e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—obesity	5.58e-07	2.07e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RHOA—obesity	5.54e-07	2.05e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOB—obesity	5.49e-07	2.04e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOS3—obesity	5.49e-07	2.03e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3R1—obesity	5.49e-07	2.03e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARA—obesity	5.47e-07	2.03e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—obesity	5.41e-07	2.01e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—obesity	5.33e-07	1.98e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AGT—obesity	5.3e-07	1.96e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LPL—obesity	5.25e-07	1.94e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—obesity	5.23e-07	1.94e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOE—obesity	5.19e-07	1.92e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAV1—obesity	5.14e-07	1.91e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOA1—obesity	5.13e-07	1.9e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GPX1—obesity	5.12e-07	1.9e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—obesity	5.07e-07	1.88e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MTOR—obesity	5.06e-07	1.88e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CB—obesity	5.06e-07	1.88e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CD36—obesity	4.99e-07	1.85e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK8—obesity	4.93e-07	1.83e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—obesity	4.92e-07	1.82e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—obesity	4.83e-07	1.79e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—obesity	4.72e-07	1.75e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—obesity	4.7e-07	1.74e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CG—obesity	4.69e-07	1.74e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARA—obesity	4.63e-07	1.72e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—obesity	4.63e-07	1.72e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—obesity	4.52e-07	1.68e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—obesity	4.51e-07	1.67e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AGT—obesity	4.49e-07	1.66e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—POMC—obesity	4.46e-07	1.65e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—INS—obesity	4.44e-07	1.64e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—obesity	4.4e-07	1.63e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOE—obesity	4.4e-07	1.63e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAV1—obesity	4.36e-07	1.62e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOA1—obesity	4.35e-07	1.61e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK8—obesity	4.28e-07	1.59e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—obesity	4.27e-07	1.58e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—obesity	4.27e-07	1.58e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—obesity	4.19e-07	1.55e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—obesity	4.18e-07	1.55e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—obesity	4.16e-07	1.54e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CD—obesity	4.12e-07	1.53e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—obesity	4.07e-07	1.51e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CG—obesity	3.97e-07	1.47e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—obesity	3.94e-07	1.46e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—obesity	3.91e-07	1.45e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3R1—obesity	3.89e-07	1.44e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NOS3—obesity	3.89e-07	1.44e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—obesity	3.83e-07	1.42e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—POMC—obesity	3.78e-07	1.4e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—INS—obesity	3.76e-07	1.39e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—obesity	3.64e-07	1.35e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—obesity	3.63e-07	1.34e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CB—obesity	3.59e-07	1.33e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—obesity	3.56e-07	1.32e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—obesity	3.55e-07	1.32e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CD—obesity	3.49e-07	1.29e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—obesity	3.44e-07	1.28e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3R1—obesity	3.29e-07	1.22e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NOS3—obesity	3.29e-07	1.22e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—obesity	3.15e-07	1.17e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—obesity	3.09e-07	1.14e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CB—obesity	3.04e-07	1.13e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—obesity	3.01e-07	1.12e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—obesity	2.9e-07	1.08e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—obesity	2.73e-07	1.01e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—obesity	2.52e-07	9.35e-06	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—obesity	2.19e-07	8.11e-06	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—obesity	1.85e-07	6.87e-06	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—obesity	1.79e-07	6.63e-06	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—obesity	1.51e-07	5.61e-06	CbGpPWpGaD
